ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-tauroc…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.15 | $-0.09 |
| Estimado | $-0.11 | $-0.18 | $-0.18 | $-0.12 |
| Sorpresa | — | — | +16.7% | +25.0% |
| Métrica | PRQR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -273.1% | -34.4% | -238.8% |
| Net Margin | -265.2% | -32.5% | -232.8% |
| FCF Margin | -338.3% | -12.6% | -325.7% |
| ROE | -85.4% | -39.2% | -46.3% |
| ROA | -37.4% | -30.9% | -6.5% |
| Current Ratio | 3.09 | 2.73 | +0.36 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -37.4% | — |
| ✗Flujo de caja operativo positivo | −€53M | −€36M |
| ✗Rentabilidad sobre activos al alza | -37.4% | -16.5% |
| ✗Caja operativa/activos supera al ROA | -46.8% | ROA -37.4% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 3.09 | 3.95 |
| ✗Sin aumentar el nº de acciones | 105M | 86M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.14 | 0.11 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -338.3% |
| ✗ROCE > 10 % | -54.1% |
| ✓Ventas > 5 %/año (3 años) | 64.2% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 287.6% |
ProQR Therapeutics N.V. cotiza a 1.31 USD y tiene una capitalización bursátil de $185M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud